The trajectory of Sildenafil presents a complex case for investors in the drug sector. While initially a blockbuster success, producing billions, the exclusivity end and the subsequent flood of generic competitors have significantly changed revenue. This poses questions about the long-term sustainability of similar medication projects and suggests